NervGen Pharma

NervGen Pharma is a regenerative medicine company focused on the advancement of innovative therapeutics for the treatment of nerve damage including spinal cord injuries (SCI) and peripheral nerve injuries (PNI).In August 2020, the company closed "best efforts" public offering of 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of $6,450,000 (the "Offering"). Each Unit was comprised of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant was exercisable to acquire one Common Share (a "Warrant Share") at an exercise price of $2.40 per Warrant Share until August 10, 2022.In July 2020, the company announced a public offering of equity securities that was expected to close in the week of August 3, 2020. Later that month, NervGen intends to issue units of the company (the "Units") at a price of $1.75 per Unit. Later that month, the company